Literature DB >> 26708526

Spectrum of phenotype and genotype of congenital isolated hypogonadotropic hypogonadism in Asian Indians.

Sandhya Nair1, Swati Jadhav1, Anurag Lila1, Varsha Jagtap1, Amol Bukan1, Reshma Pandit1, Alka Ekbote2, Mala Dharmalingam3, Prasanna Kumar4, Pramila Kalra3, Pramod Gandhi1, Rama Walia5, Shilpa Sankhe1, Vijaya Raghavan1, Vyankatesh Shivane1, Padma Menon1, Tushar Bandgar1, Nalini Shah1.   

Abstract

BACKGROUND: Congenital isolated hypogonadotropic hypogonadism (IHH) is caused due to defect in GnRH neuronal development, migration and action. Although genetic aetiology of IHH is increasingly being studied, Asian Indian data on phenotypic spectrum and genetic basis are scarce.
OBJECTIVE: To investigate the phenotypic and genotypic spectrum of IHH in Asian Indian subjects. DESIGN, SETTING AND
SUBJECTS: A cohort of 135 IHH probands were characterized phenotypically for reproductive and nonreproductive features and screened for rare sequence variations (RSVs) in five genes KAL1, FGFR1, FGF8, GNRHR and KISS1R. RESULT: Of 135 probands [56 normosmic IHH (nIHH) and 79 Kallmann syndrome (KS)], 20 were familial cases. KS group had more male dominance (M:F ratio of 8:1) as compared to nIHH group (M:F ratio of 1·5:1). Complete absence of puberty was more prevalent in KS probands (81% in KS vs 46% in nIHH). The prevalence of MRI abnormalities was more in anosmic group (92·8%) as compared to hyposmic (37·5%) and normosmic groups (15·4%). No particular nonreproductive phenotypic predominance was seen in any group. Genotyping revealed rare sequence variation (RSV) detection rate of 15·5% in five genes studied: (KAL1 - 4·4%, FGFR1 - 4·4%, GNRHR - 6·7%, oligogenicity - 1·5%). Prevalence of RSV was more common in familial cases (35%) as compared to sporadic (12·2%). GNRHR RSV p.C279Y (not reported in patients of ethnicities other than south Asians) was recurring in four unrelated patients.
CONCLUSION: In our cohort, 60% were KS with majority of males and a severe reproductive phenotype as against nIHH. Contribution of the genetic burden for the five genes studied was 15·5%. RSV p.C279Y in GNRHR may have a founder effect originating from south Asia. This study provides a model for molecular and phenotypic representation of Asian Indian subjects with IHH.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26708526     DOI: 10.1111/cen.13009

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  The Use of Variant Maps to Explore Domain-Specific Mutations of FGFR1.

Authors:  L A Lansdon; H V Bernabe; N Nidey; J Standley; M J Schnieders; J C Murray
Journal:  J Dent Res       Date:  2017-08-21       Impact factor: 6.116

2.  Defects in GnRH Neuron Migration/Development and Hypothalamic-Pituitary Signaling Impact Clinical Variability of Kallmann Syndrome.

Authors:  Małgorzata Kałużna; Bartłomiej Budny; Michał Rabijewski; Jarosław Kałużny; Agnieszka Dubiel; Małgorzata Trofimiuk-Müldner; Elżbieta Wrotkowska; Alicja Hubalewska-Dydejczyk; Marek Ruchała; Katarzyna Ziemnicka
Journal:  Genes (Basel)       Date:  2021-06-05       Impact factor: 4.096

Review 3.  Kallmann Syndrome Due to Heterozygous Mutation in SOX10 Coexisting With Waardenburg Syndrome Type II: Case Report and Review of Literature.

Authors:  Kan Chen; Haoyu Wang; Yaxin Lai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-01       Impact factor: 5.555

4.  Exploring the Genetic Diversity of Isolated Hypogonadotropic Hypogonadism and Its Phenotypic Spectrum: A Case Series.

Authors:  Vijay Sheker Reddy Danda; Srinivas Rao Paidipelly; Madhavi Verepula; Piyush Lodha; Krishna Reddy Thaduri; Chaitanya Konda; Apsia Ruhi
Journal:  J Reprod Infertil       Date:  2021 Jan-Mar

5.  The diagnostic value of the olfactory evaluation for congenital hypogonadotropic hypogonadism.

Authors:  Bingqing Yu; Kepu Chen; Jiangfeng Mao; Bo Hou; Hui You; Xi Wang; Min Nie; Qibin Huang; Rui Zhang; Yiyi Zhu; Bang Sun; Feng Feng; Wen Zhou; Xueyan Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.